The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure

Journal of Cardiovascular Translational Research

Volumn 6, Issue 3, 2013, Pages 388-397

  Guo, Yutao ^b   Lip, Gregory Y H ^a   Apostolakis, Stavros ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Anticoagulant; Antiplatelet; Atrial fibrillation; Heart failure; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; COUMARIN; EVEROLIMUS; IRBESARTAN; PACLITAXEL; PLACEBO; PRASUGREL; TACROLIMUS; TICAGRELOR; TRIFLUSAL; WARFARIN;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELDERLY CARE; EMBOLISM; EMBOLISM PREVENTION; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LACUNAR STROKE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STENTS; STROKE; TREATMENT OUTCOME;

EID: 84877742568     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9427-y     Document Type: Article

References (61)

1. Potpara, T. S., Lip, G. Y., & Apostolakis, S. (2012). New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart, 98, 1341-1347.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace (in press).
3. Lip, G. Y., Ponikowski, P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P., Rasmussen, L. H., Marin, F., Lane, D. A., & ESC Task Force. (2012). Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail, 14, 681-695.
4. Vemmos, K., Ntaios, G., Savvari, P., Vemmou, A. M., KorobokiE, M. E., Kounali, A., & Lip, G. Y. (2012). Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail, 14, 211-218.
5. The Stroke Prevention in Atrial Fibrillation Investigators. (1991). Stroke prevention in atrial fibrillation study: final results. Circulation, 84, 527-539.
6. The Stroke Prevention in Atrial Fibrillation Investigators. (1993). A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis, 3, 181-188.
7. Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007). Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146, 857-867.
8. Aguilar M, Hart R (2005) Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 19:CD001925.
9. Antithrombotic Trialists' (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., Kearney, P., Meade, T., Patrono, C., Roncaglioni, M. C., & Zanchetti, A. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849-1860.
10. ACTIVE Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., Pfeffer, M., Hohnloser, S., & Yusuf, S. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367, 1903-1912.
11. Active Investigators, Connolly, S. J., Pogue, J., Hart, R. G., Hohnloser, S. H., Pfeffer, M., Chrolavicius, S., & Yusuf, S. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 360, 2066-2078.
12. Lee, S., Shafe, A. C., & Cowie, M. R. (2011). UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open, 1, e000269.
13. Rietbrock, S., Plumb, J. M., Gallagher, A. M., & van Staa, T. P. (2009). How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ThrombHaemost, 101, 527-534.
14. Olesen, J. B., Lip, G. Y., Lindhardsen, J., Lane, D. A., Ahlehoff, O., Hansen, M. L., Raunsø, J., Tolstrup, J. S., Hansen, P. R., Gislason, G. H., & Torp-Pedersen, C. (2011). Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost, 106, 739-749.
15. Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., Murray, E., & BAFTA investigators; Midland Research Practices Network (MidReC). (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, 370, 493-503.
16. Jowett, S., Bryan, S., Mant, J., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Hobbs, F. D. (2011). Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke, 42, 1717-1721.
17. Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., & Channer, K. S. (2007). A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing, 36, 151-156.
18. van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F. D., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., Boode, B., Ezekowitz, M. D., & Singer, D. E. (2009). Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke, 40, 1410-1416.
19. Sato, H., Ishikawa, K., Kitabatake, A., Ogawa, S., Maruyama, Y., Yokota, Y., Fukuyama, T., Doi, Y., Mochizuki, S., Izumi, T., Takekoshi, N., Yoshida, K., Hiramori, K., Origasa, H., Uchiyama, S., Matsumoto, M., Yamaguchi, T., Hori, M., & Japan Atrial Fibrillation Stroke Trial Group. (2006). Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke, 37, 447-451.
20. De Berardis, G., Lucisano, G., D'Ettorre, A., Pellegrini, F., Lepore, V., Tognoni, G., & Nicolucci, A. (2012). Association of aspirin use with major bleeding in patients with and without diabetes. JAMA, 307, 2286-2294.
21. Watson, T., Shantsila, E., & Lip, G. Y. (2009). Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet, 373, 155-166.
22. Benbir, G., Uluduz, D., Ince, B., & Bozluolcay, M. (2007). Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg, 109, 485-490.
23. 2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke, 42, 930-934.
24. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. (1998). Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med, 128, 639-647.
25. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M., & TRITON-TIMI 38 Investigators. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357, 2001-2015.
26. Roe, M. T., Armstrong, P. W., Fox, K. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C. D., Merkely, B., Gasparovic, V., Corbalan, R., Cintezǎ, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., Ohman, E. M., & TRILOGY ACS Investigators. (2010). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med, 367, 1297-1309.
27. James, S. K., Roe, M. T., Cannon, C. P., Cornel, J. H., Horrow, J., Husted, S., Katus, H., Morais, J., Steg, P. G., Storey, R. F., Stevens, S., Wallentin, L., Harrington, R. A., & Study Group, P. L. A. T. O. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, d3527. doi: 10.1136/bmj.d3527.
28. Holmes, D. R., Jr., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010). ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol, 56, 321-341.
29. Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., Fernandez-Aviles, F., Gershlick, A. H., Giannuzzi, P., Halvorsen, S., Huber, K., Juni, P., Kastrati, A., Knuuti, J., Lenzen, M. J., Mahaffey, K. W., Valgimigli, M., Van't Hof, A., Widimsky, P., Zahger, D., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Document Reviewers, Hasdai, D., Astin, F., Aström-Olsson, K., Budaj, A., Clemmensen, P., Collet, J. P., Fox, K. A., Fuat, A., Gustiene, O., Hamm, C. W., Kala, P., Lancellotti, P., Maggioni, A. P., Merkely, B., Neumann, F. J., Piepoli, M. F., Van de Werf, F., Verheugt, F., & Wallentin, L. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 33, 2569-2619.
30. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R. S., Sim, K. H., Lewis, B. S., Van Mieghem, W., Lip, G. Y., Kim, J. H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A. L., Munawar, M., O'Donnell, M., Lawrence, J., Lewis, G., Afzal, R., Yusuf, S., & AVERROES Steering Committee and Investigators. (2011). Apixaban in patients with atrial fibrillation. N Engl J Med, 364, 806-817.
31. Diener, H. C., Eikelboom, J., Connolly, S. J., Joyner, C. D., Hart, R. G., Lip, G. Y., O'Donnell, M., Hohnloser, S. H., Hankey, G. J., Shestakovska, O., Yusuf, S., & AVERROES Steering Committee and Investigators. (2012). Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol, 11, 225-231.
32. Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., Abildstrøm, S. Z., Poulsen, H. E., Køber, L., & Torp-Pedersen, C. (2010). Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 170, 1433-1441.
33. Lip, G. Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, K. J., Cuisset, T., Kirchhof, P., Marín, F., & European Society of Cardiology Working Group on Thrombosis. (2010). Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost, 103, 13-28.
34. Lane, D. A., Kamphuisen, P. W., Minini, P., Büller, H. R., & Lip, G. Y. (2011). Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest, 140, 146-155.
35. De Ferrari, G. M., Klersy, C., Ferrero, P., Fantoni, C., Salerno-Uriarte, D., Manca, L., Devecchi, P., Molon, G., Revera, M., Curnis, A., Sarzi Braga, S., Accardi, F., Salerno-Uriarte, J. A., & ALPHA Study Group. (2007). Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail, 9, 502-509.
36. Dickstein, K., Bogale, N., Priori, S., Auricchio, A., Cleland, J. G., Gitt, A., Limbourg, T., Linde, C., van Veldhuisen, D. J., Brugada, J., & Scientific Committee, National Coordinators. (2009). The European cardiac resynchronization therapy survey. Eur Heart J, 30, 2450-2460.
37. Nieminen, M. S., Brutsaert, D., Dickstein, K., Drexler, H., Follath, F., Harjola, V. P., Hochadel, M., Komajda, M., Lassus, J., Lopez-Sendon, J. L., Ponikowski, P., Tavazzi, L., & EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. (2006). EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart, J27, 2725-2736.
38. Mulder, B. A., Van Veldhuisen, D. J., Crijns, H. J., Böhm, M., Cohen-Solal, A., Babalis, D., Roughton, M., Flather, M. D., Coats, A. J., & Van Gelder, I. C. (2012). Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail, 14, 1171-1178.
39. Dahlstrom, U., Hakansson, J., Swedberg, K., & Waldenstrom, A. (2009). Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail, 11, 92-98.
40. Holmström A, Sigurjonsdottir R, Edner M, Jonsson A, Dahlström U, Fu ML (2012) Increased comorbidities in heart failure patients ≥85 years but declined from >90 years: data from the Swedish Heart Failure Registry. Int J Cardiol (in press)
41. de Peuter, O. R., Lip, G. Y., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2011). Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. Eur J Heart Fail, 489.
42. Witt, B. J., Gami, A. S., Ballman, K. V., Brown, R. D., Jr., Meverden, R. A., Jacobsen, S. J., & Roger, V. L. (2007). The incidence of ishcemic stroke in chronic heart failure: a meta-analysis. J Card Fail, 13, 489-496.
43. Albert, V. P., Bos, M. J., Koudstaal, P. J., Hofman, A., Witteman, J. C., Stricker, B. H., & Breteler, M. M. (2010). Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol, 25, 807-812.
44. Kannel, W. B., Wolf, P. A., & Verter, J. (1983). Mainfestations of coronary disease predisposing to stroke: the Framingham Study. JAMA, 250, 2942-2946.
45. Lip GY, Rasmussen LH, Skjøth F, Overvad K, Larsen TB (2012) Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open. 2:e000975. doi: 10.1136/bmjopen-2012- 000975.
46. Banerjee, A., Taillandier, S., Olesen, J. B., Lane, D. A., Lallemand, B., Lip, G. Y., & Fauchier, L. (2012). Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail, 14, 295-301.
47. Shantsila, E., & Lip, G. Y. (2011). The risk of thromboembolism in heart failure: does it merit anticoagulation therapy? Am J Cardiol, 107, 558-560.
48. Lip, G. Y., & Gibbs, C. R. (1999). Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am CollCardiol, 33, 1424-1426.
49. Freudenberger, R. S., Schumaecker, M. M., & Homma, S. (2010). What is the appropriate approach to prevention of thromboembolism in heart failure? Thromb Haemost, 103, 489-495.
50. Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., Spencer, F. A., & American College of Chest Physicians. (2012). Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e637S-e668S.
51. Cleland, J. G., Findlay, I., Jafri, S., Sutton, G., Falk, R., Bulpitt, C., Prentice, C., Ford, I., Trainer, A., & Poole-Wilson, P. A. (2004). The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart, J148, 157-164.
52. Massie, B. M., Collins, J. F., Ammon, S. E., Armstrong, P. W., Cleland, J. G., Ezekowitz, M., Jafri, S. M., Krol, W. F., O'Connor, C. M., Schulman, K. A., Teo, K., Warren, S. R., & WATCH Trial Investigators. (2009). Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation, 119, 1616-1624.
53. Cokkinos, D. V., Haralabopoulos, G. C., Kostis, J. B., Toutouzas, P. K., & HELAS Investigators. (2006). Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail, 8, 428-432.
54. Homma, S., Thompson, J. L., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., Ammon, S. E., Graham, S., Sacco, R. L., Mann, D. L., Mohr, J. P., Massie, B. M., Labovitz, A. J., Anker, S. D., Lok, D. J., Ponikowski, P., Estol, C. J., Lip, G. Y., Di Tullio, M. R., Sanford, A. R., Mejia, V., Gabriel, A. P., del Valle, M. L., Buchsbaum, R., & Investigators, W. A. R. C. E. F. (2012). Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med, 366, 1859-1869.
55. McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y., Maggioni, A. P., Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P. T., Voors, A. A., Zannad, F., Zeiher, A., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Document Reviewers, McDonagh, T., Sechtem, U., Bonet, L. A., Avraamides, P., Ben Lamin, H. A., Brignole, M., Coca, A., Cowburn, P., Dargie, H., Elliott, P., Flachskampf, F. A., Guida, G. F., Hardman, S., Iung, B., Merkely, B., Mueller, C., Nanas, J. N., Nielsen, O. W., Orn, S., Parissis, J. T., & Ponikowski, P. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 14, 803-869.
56. Ahrens, I., Lip, G. Y., & Peter, K. (2010). New oral anticoagulant drugs in cardiovascular disease. ThrombHaemost, 104, 49-60.
57. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E. D., & Andersen, B. (1989). Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet, 1, 175-179.
58. Hellemons, B. S., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999). Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin. BMJ, 319, 958-964.
59. Pérez-Gómez, F., Alegría, E., Berjón, J., Iriarte, J. A., Zumalde, J., Salvador, A., Mataix, L., & Investigators, N. A. S. P. E. A. F. (2004). Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am CollCardiol, 44, 1557-1566.
60. Gulløv, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., & Boysen, G. (1989). Fixed minidose warfarin and aspirin alone and in combination vs. adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med, 158, 1513-1521.
61. The Stroke Prevention in Atrial Fibrillation Investigators. (1994). Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet, 343, 687-691.